Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06943872 · ClinicalTrials.gov registry record · Phase 3

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

A Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by BeOne Medicines.

Recruiting
Registry status
Phase 3
Development phase
630
Enrollment target
20
Study locations

NCT06943872: Recruiting Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by BeOne Medicines.

NCT06943872 is a Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 630 participants, above the 178-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (254% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06943872, a Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, is actively recruiting participants, sponsored by BeOne Medicines.

RECRUITING
Registry status
Phase 3
Development phase
630 participants
Enrollment target
20
Study locations

Study Summary

The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.

Primary Outcome

PFS is defined as the time from randomization to the date of progression or death, whichever occurs first.

Conditions Studied

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Interventions

  • DRUG Obinutuzumab
  • DRUG Venetoclax
  • DRUG Sonrotoclax
  • DRUG Rituximab

Study Locations (20)

California

  • Uci Health Laguna Hills - Laguna Hills
  • Chao Family Comprehensive Cancer Center - Orange
  • Stanford Cancer Institute - Palo Alto
  • Scripps Prebys Cancer Center - San Diego

Connecticut

  • Yale University, Yale Cancer Center - New Haven
  • Eastern Connecticut Hematology and Oncology - Norwich

Illinois

  • Northwestern University - Chicago
  • Illinois Cancer Specialists (Niles) Usor - Niles

New York

  • Memorial Sloan Kettering Cancer Center Mskcc - New York
  • Clinical Research Alliance, Inc - Westbury

North Carolina

  • University of North Carolina At Chapel Hill - Chapel Hill
  • Levine Cancer Center - Charlotte

Colorado

  • Rocky Mountain Cancer Centers (Williams) Usor - Aurora

Kentucky

  • University of Louisville, Brown Cancer Center - Louisville

Louisiana

  • Mary Bird Perkins Cancer Center - Baton Rouge

Trial Details

FieldValue
Enrollment Target 630 participants
Start Date 2025-06-11
Est. Completion 2031-12
Phase Phase 3
BeOne Medicines

29 total trials

What NCT06943872 shows while recruiting

NCT06943872 is an interventional study that assigns participants to a tested intervention. The registered 630 participants enrollment target is mid-sized for trials with a published cap, above the 178-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (254% higher).

The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 4 interventions - of which Obinutuzumab is the first listed.

NCT06943872 names 20 study sites across 13 states, led by California, Connecticut, Illinois.

Frequently Asked Questions

What is clinical trial NCT06943872 about?

NCT06943872 is a clinical study titled "A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)". The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituxim...

What is the current status of trial NCT06943872?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 630 participants. The study started on 2025-06-11. Estimated completion is 2031-12.

What conditions does trial NCT06943872 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.

What interventions are being tested in trial NCT06943872?

The interventions under investigation include: Obinutuzumab (DRUG), Venetoclax (DRUG), Sonrotoclax (DRUG), Rituximab (DRUG).

Who is sponsoring clinical trial NCT06943872?

This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06943872 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06943872's enrollment target sits among peer trials

630 12th of 187 higher than 176 of 187 other Chronic Lymphocytic Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04704921 · 630 participants · Phase 2

    Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

  • NCT04707729 · 630 participants · NA

    ROX Index for the Timing of Intubation in Nasal High Flow

  • NCT05061550 · 630 participants · Phase 2

    Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  • NCT05224440 · 630 participants · NA

    National Sponsorship Program for Transitioning Service Members

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06943872

Source: ClinicalTrials.gov NCT06943872, the US trial registry maintained by the National Library of Medicine. NCT06943872 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.